Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.creatorCorremans, R
dc.creatorAdao, R
dc.creatorDe Keulenaer, GW
dc.creatorLeite Moreira, AF
dc.creatorBrás-Silva C
dc.description.abstractAnthracycline chemotherapy has a prominent role in treating many forms of cancer. Unfortunately, cardiotoxic side effects represent a serious limitation to their use, with doxorubicin being the leading drug of the group. Indeed, anthracycline-induced cardiomyopathy is an important public health concern because it may not be detected for many years and remains a lifelong threat. Even after decades of investigation, neither the exact mode of action of anthracyclines nor the pathways leading to their side effect are fully understood. It is increasingly important to establish collaboration between oncologists and cardiologists to improve the management of cancer patient receiving anthracyclines. This article reviews the clinical course, pathogenesis, cardiac monitoring and new concepts in diagnosing and preventing anthracycline-induced cardiotoxicity.
dc.subjectCiências da Saúde, Ciências médicas e da saúde
dc.subjectHealth sciences, Medical and Health sciences
dc.titleUpdate on pathophysiology and preventive strategies of anthracycline-induced cardiotoxicity
dc.typeArtigo em Revista Científica Internacional
dc.contributor.uportoFaculdade de Medicina
dc.subject.fosCiências médicas e da saúde
dc.subject.fosMedical and Health sciences
Appears in Collections:FMUP - Artigo em Revista Científica Internacional

Files in This Item:
File Description SizeFormat 
  Restricted Access
1.15 MBAdobe PDF    Request a copy from the Author(s)

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.